Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
ARCT Stock Chart & Stats
$6.79
-$1.70(-8.19%)
At close: 4:00 PM EST
$6.79
-$1.70(-8.19%)
Day’s Range― - ―
52-Week Range$5.85 - $24.17
Previous CloseN/A
Volume109.32K
Average Volume (3M)829.62K
Market Cap
$242.49M
Enterprise Value$128.45M
Total Cash (Recent Filing)$180.36M
Total Debt (Recent Filing)$21.86M
Price to Earnings (P/E)―
Beta2.33
Next Earnings
Mar 02, 2026EPS Estimate
-0.79Last Dividend Ex-Date
Jan 08, 2013Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding27,154,530
10 Day Avg. Volume934,920
30 Day Avg. Volume829,622
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.90
Price to Sales (P/S)3.31
P/FCF Ratio-7.59
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue1.40
Enterprise Value/Gross Profit1.45
Enterprise Value/Ebitda-1.87
Forecast
1Y Price Target
$31.29Price Target Upside360.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe cash runway extends into 2028, suggesting financial stability and capability to fund ongoing projects.
Market PotentialARCT-032 could eventually generate ~$1B+ as it opens the door to ~8% of the CF market, targeting patients ineligible for modulators.
Positive Clinical DataVery positive ARC-810 readout for platform showing that Arcturus' highly purified mRNA gets into the liver cells of patients and generates functional enzymes.
Bears Say
Clinical Trial ChallengesArcturus shares are down 48% year-to-date after delivering Phase II clinical data of daily inhaled ARCT-032 in cystic fibrosis (CF) that did not meet management’s 3% FEV1.0 improvement from baseline.
Efficacy ConcernsThe cystic fibrosis (CF) program is not considered worth progressing towards later stage clinical trials due to lack of efficacy signals.
Regulatory DelaysThe company's plans for US BLA for KOSTAIVE have been paused due to regulatory changes, impacting their vaccine strategy.
Arcturus Therapeutics News
ARCT FAQ
What was Arcturus Therapeutics’s price range in the past 12 months?
Arcturus Therapeutics lowest stock price was $5.85 and its highest was $24.17 in the past 12 months.
What is Arcturus Therapeutics’s market cap?
Arcturus Therapeutics’s market cap is $242.49M.
When is Arcturus Therapeutics’s upcoming earnings report date?
Arcturus Therapeutics’s upcoming earnings report date is Mar 02, 2026 which is in 92 days.
How were Arcturus Therapeutics’s earnings last quarter?
Arcturus Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.899 by $0.409.
Is Arcturus Therapeutics overvalued?
According to Wall Street analysts Arcturus Therapeutics’s price is currently Undervalued.
Does Arcturus Therapeutics pay dividends?
Arcturus Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Arcturus Therapeutics dividends here
What is Arcturus Therapeutics’s EPS estimate?
Arcturus Therapeutics’s EPS estimate is -0.79.
How many shares outstanding does Arcturus Therapeutics have?
Arcturus Therapeutics has 27,154,530 shares outstanding.
What happened to Arcturus Therapeutics’s price movement after its last earnings report?
Arcturus Therapeutics reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.899. Following the earnings report the stock price went down -1.253%.
Which hedge fund is a major shareholder of Arcturus Therapeutics?
Currently, no hedge funds are holding shares in ARCT
Arcturus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.29 (360.82% Upside)
$31.29 (360.82% Upside)
Hedge Fund Trend
Decreased
By 556.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 8.9%
Last 30 Days ▼ 8.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.29%
12-Months-Change
Fundamentals
Return on Equity
-27.43%
Trailing 12-Months
Asset Growth
-20.42%
Trailing 12-Months
Company Description
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
ARCT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive progress in clinical trials and strategic partnerships, but was overshadowed by significant financial challenges, including revenue decline and increased net loss. The indefinite delay in the Costave BLA filing represents a major hurdle for the company's commercial prospects in the US market.View all ARCT earnings summariesARCT Stock 12 Month Forecast
Average Price Target
$31.29
▲(360.82% Upside)
Technical Analysis
Rigel
―
Arvinas Holding Company
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Erasca
―
Ownership Overview
8.42% Insiders
30.48% Mutual Funds
25.46% Other Institutional Investors
13.18% Public Companies and Individual Investors